<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131000</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-CL-004</org_study_id>
    <nct_id>NCT01131000</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Trial To Evaluate The Efficacy, Safety, and Pharmacokinetics of Ibuprofen Injection in Adult Febrile Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of intravenous ibuprofen on
      reducing fever at 4 hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of a single 400 mg dose of
      intravenous ibuprofen on reducing fever greater than or equal to 101.0ºF (38.3ºC), as
      compared with the efficacy of parallel placebo treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of patients with fever reduction to less than 101.0 degree fahrenheit following a single dose of intravenous ibuprofen.</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Fever</condition>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Intravenous ibuprofen, 100 mg, Single-dose</description>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Intravenous ibuprofen, 200mg, single dose</description>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Intravenous ibuprofen, 400 mg, Single-dose</description>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Normal Saline, 100 ml, Single-dose</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>0.9 % NaCL; 0.9 % Sodium Chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be hospitalized

          2. Have new (not chronic, within last 7 days) onset of fever, documented by temperature
             greater than or equal to 101.0ºF (38.3ºC)

          3. Have adequate intravenous access

          4. Have the ability to understand the requirements of the study, be willing to provide
             written informed consent (as evidenced by signature on an informed consent document
             approved by an Institutional Review Board), and agree to abide by the study
             restrictions and to return for the required assessments

        Exclusion Criteria:

          1. Be less than 18 years of age

          2. Have received antipyretic drug therapy (e.g., aspirin, other NSAIDs, or acetaminophen)
             within 4 hours before dosing

          3. Have any history of allergy or hypersensitivity to any component of IVIb, NSAIDs
             (including aspirin), or COX-2 inhibitors

          4. Be pregnant or nursing

          5. Have a history of severe head trauma that required current hospitalization,
             intracranial surgery, or stroke within the previous 30 days, or any history of
             intracerebral arteriovenous malformation, cerebral aneurysm, or central nervous system
             mass lesions

          6. Weigh less than 40 kg

          7. Have a history of congenital bleeding diatheses (e.g., hemophilia) or any active
             clinically significant bleeding, or have underlying platelet dysfunction, including
             (but not limited to) idiopathic thrombocytopenic purpura, disseminated intravascular
             coagulation, or congenital platelet dysfunction

          8. Have gastrointestinal bleeding that has required medical intervention within the
             previous 6 weeks (unless definitive surgery has been performed)

          9. Have a platelet count less than 30,000/mm3

         10. Be receiving full dose anticoagulation therapy

         11. Have fever secondary to blood or drug reaction

         12. Have an expected life span of less than 14 days because of imminent withdrawal of life
             support or severity of illness

         13. Be receiving treatment with corticosteroids (Patients who are expected to receive
             corticosteroids during the Treatment Period or through Hour 120 of the Post-treatment
             Period are not eligible.)

         14. Have neurogenic fever

         15. Be on dialysis, have oliguria or creatinine greater than 3.0 mg/dL, or be receiving
             nephrotoxic drugs

         16. Have had major surgery within the past 12 hours, unless adequate hemostasis has been
             achieved

         17. Have received another investigational drug within the past 30 days

         18. Become afebrile (temperature below 101.0ºF [38.3ºC]) before dosing and not redevelop
             fever entry criteria during this hospitalization

         19. Be otherwise unsuitable for the study, in the opinion of the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon Bernard, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Cumberland Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Regional Medical Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moses H. Cone Memorial Hospital</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Healthcare - University Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skyline Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ben Taub General Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Mater Misericordiae Hospital</name>
      <address>
        <city>New Lambton</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mahidol University Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>May 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2010</study_first_posted>
  <last_update_submitted>May 25, 2010</last_update_submitted>
  <last_update_submitted_qc>May 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>A. J. Kazimi, Chief Executive Office</name_title>
    <organization>Cumberland Pharmaceuticals Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

